These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2029016)

  • 1. Improvement in severe onchocercal skin disease after a single dose of ivermectin.
    Pacqué M; Elmets C; Dukuly ZD; Muñoz B; White AT; Taylor HR; Greene BM
    Am J Med; 1991 May; 90(5):590-4. PubMed ID: 2029016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ivermectin treatment of hyperreactive onchodermatitis (sowda) in Liberia.
    Darge K; Büttner DW
    Trop Med Parasitol; 1995 Dec; 46(4):206-12. PubMed ID: 8826099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ivermectin treatment of onchocercal skin lesions: observations from a placebo-controlled, double-blind trial in Malawi.
    Burnham G
    Am J Trop Med Hyg; 1995 Mar; 52(3):270-6. PubMed ID: 7694970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivermectin treatment in severe asymmetric reactive onchodermatitis (sowda) in Sudan.
    Baraka OZ; Mahmoud BM; Ali MM; Ali MH; el Sheikh EA; Homeida MM; Mackenzie CD; Williams JF
    Trans R Soc Trop Med Hyg; 1995; 89(3):312-5. PubMed ID: 7660447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of ivermectin on onchocercal skin disease and severe itching: results of a multicentre trial.
    Brieger WR; Awedoba AK; Eneanya CI; Hagan M; Ogbuagu KF; Okello DO; Ososanya OO; Ovuga EB; Noma M; Kale OO; Burnham GM; Remme JH
    Trop Med Int Health; 1998 Dec; 3(12):951-61. PubMed ID: 9892280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Onchocerciasis].
    Enk CD; Gardlo K; Ruzicka T; BenEzra D
    Hautarzt; 2003 Jun; 54(6):513-7. PubMed ID: 12759735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivermectin does not reduce the burden of itching in an onchocerciasis endemic community.
    Whitworth JA; Luty AJ; Maude GH; Morgan D; Downham MD; Taylor DW
    Trans R Soc Trop Med Hyg; 1992; 86(3):281-3. PubMed ID: 1412653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of reactive onchocercal skin lesions during a placebo-controlled trial with ivermectin among persons without lesions at baseline.
    Brieger WR; Kale OO; Ososanya OO
    Trop Doct; 2001 Apr; 31(2):96-8. PubMed ID: 11321284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onchocerciasis situation in the Tukuyu focus of southwest Tanzania after ten years of ivermectin mass treatment.
    Mweya CN; Kalinga AK; Kabula B; Malley KD; Ruhiso MH; Maegga BT
    Tanzan Health Res Bull; 2007 Sep; 9(3):174-9. PubMed ID: 18087895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of 5 years of annual treatment with ivermectin (Mectizan) on the prevalence and morbidity of onchocerciasis in the village of Gami in the Central African Republic.
    Kennedy MH; Bertocchi I; Hopkins AD; Meredith SE
    Ann Trop Med Parasitol; 2002 Apr; 96(3):297-307. PubMed ID: 12061976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa.
    Murdoch ME; Asuzu MC; Hagan M; Makunde WH; Ngoumou P; Ogbuagu KF; Okello D; Ozoh G; Remme J
    Ann Trop Med Parasitol; 2002 Apr; 96(3):283-96. PubMed ID: 12061975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of semiannual treatments of ivermectin on the prevalence and intensity of Onchocerca volvulus skin infection, ocular lesions, and infectivity of Simulium ochraceum populations in southern Mexico.
    Rodriguez-Perez MA; Rodriguez MH; Margeli-Perez HM; Rivas-Alcala AR
    Am J Trop Med Hyg; 1995 May; 52(5):429-34. PubMed ID: 7771609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-control relationship of onchocercal skin disease with onchocercal infection in Guinea Savanna, Northern Nigeria.
    Murdoch ME; Murdoch IE; Evans J; Yahaya H; Njepuome N; Cousens S; Jones BR; Abiose A
    PLoS Negl Trop Dis; 2017 Mar; 11(3):e0005489. PubMed ID: 28355223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ivermectin in human onchocerciasis: a clinical-pathological study of skin lesions before and three days after treatment.
    Vuong PN; Traoré S; Wanji S; Diarrassouba S; Balaton A; Bain O
    Ann Parasitol Hum Comp; 1992; 67(6):194-6. PubMed ID: 1301733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Field-Based Evidence of Single and Few Doses of Annual Ivermectin Treatment Efficacy in Eliminating Skin Microfilaria Load after a Decade of Intervention.
    Osue HO
    Ethiop J Health Sci; 2017 Mar; 27(2):129-138. PubMed ID: 28579708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of single-dose ivermectin therapy on human Onchocerca volvulus infection with onchocercal ocular involvement.
    Newland HS; White AT; Greene BM; D'Anna SA; Keyvan-Larijani E; Aziz MA; Williams PN; Taylor HR
    Br J Ophthalmol; 1988 Aug; 72(8):561-9. PubMed ID: 3046657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual host factors associated with Onchocerca volvulus microfilarial densities 15, 80 and 180 days after a first dose of ivermectin.
    Pion SD; Grout L; Kamgno J; Nana-Djeunga H; Boussinesq M
    Acta Trop; 2011 Sep; 120 Suppl 1():S91-9. PubMed ID: 20497765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stigma associated with onchocercal skin disease among those affected near the Ofiki and Oyan Rivers in western Nigeria.
    Brieger WR; Oshiname FO; Ososanya OO
    Soc Sci Med; 1998 Oct; 47(7):841-52. PubMed ID: 9722105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy of onchocerciasis with high doses of diethylcarbamazine or a single dose of ivermectin: microfilaria levels and side effects.
    Albiez EJ; Newland HS; White AT; Kaiser A; Greene BM; Taylor HR; Büttner DW
    Trop Med Parasitol; 1988 Mar; 39(1):19-24. PubMed ID: 3291074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of onchocerciasis and associated dermatologic and ophthalmic pathologies after 27 years of ivermectin mass drug administration in the middle belt of Ghana.
    Otabil KB; Basáñez MG; Ankrah B; Opoku SA; Kyei DO; Hagan R; Ababio R; Bart-Plange EJ; Babae TN; Kudzordzi PC; Darko VA; Bamfo JG; Ameyaw J; Raji AS; Hadermann A; Schallig HDFH; Colebunders R
    Trop Med Int Health; 2023 Nov; 28(11):844-854. PubMed ID: 37846505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.